Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors

12 Aug 2020

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICIs) are an important treatment modality that must be considered for patients with lung adenocarcinoma (LUAD). However, ICIs are effective only in some of these patients. Therefore, identifying biomarkers that accurately predict the prognosis of patients with LUAD treated with ICIs can help maximize their therapeutic benefits. This study aimed to identify a new potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32903385
DOI: 10.3389/fphar.2020.01213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint InhibitorsPMID 32903385Read ↗

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read ↗

ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.Semantic proximity Read ↗

Identification of gene signatures relevant to the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Evaluation of NTRK3 mutation and a mutation-based gene set as biomarkers for immunotherapy outcomes in multiple cancersSemantic proximity Read ↗

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy.Semantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.Semantic proximity Read ↗

Identification of Key Genes and Clinical Feature Analyses of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma.Semantic proximity Read ↗

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic AnalysisSemantic proximity Read ↗

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations.Semantic proximity Read ↗

Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.